Berarducci Antonio, Sian Inderpaul S, Ling Roland
West of England Eye Unit, RD&EH, Exeter - United Kingdom.
Eur J Ophthalmol. 2014 Jul-Aug;24(4):620-2. doi: 10.5301/ejo.5000436. Epub 2014 Feb 3.
Dexamethasone intravitreal implant is an approved preparation in the treatment of macular edema. The most common adverse reactions are increased intraocular pressure and cataract but the inadvertent injection of the dexamethasone implant into the capsular bag is an extremely rare event.
We present a case of a 78-year-old man treated for persistence of cystoid macular edema (CME) with Ozurdex intravitreal implant in which the procedure was complicated by the injection of the dexamethasone implant into the lens body and discuss the management.
The patient underwent phacoemulsification of the lens, replacement of the Ozurdex, and implant of a 3-piece lens in the posterior chamber.
The injection of an intravitreal dexamethasone implant (Ozurdex) into the lens body is an extremely rare complication that can be effectively and successfully managed with the surgical extraction of the implant from the lens body and implant of a 3-piece intraocular lens in the sulcus.
地塞米松玻璃体内植入物是一种经批准用于治疗黄斑水肿的制剂。最常见的不良反应是眼压升高和白内障，但地塞米松植入物意外注入晶状体囊袋是极为罕见的事件。
我们报告一例78岁男性患者，因持续性黄斑囊样水肿（CME）接受Ozurdex玻璃体内植入物治疗，该手术因将地塞米松植入物注入晶状体体而变得复杂，并讨论了处理方法。
患者接受了晶状体超声乳化术、更换Ozurdex，并在后房植入了三片式人工晶状体。
将玻璃体内地塞米松植入物（Ozurdex）注入晶状体体是一种极为罕见的并发症，可通过手术从晶状体体中取出植入物并在睫状沟植入三片式人工晶状体进行有效且成功的处理。
